Healthcare
24 articles in this industry.
Eli Lilly (LLY): What This Company Actually Does
A plain-English read of Eli Lilly's business model, built directly from its SEC filings — no hype, just where the money comes from.
2026-09-28The StoryEli Lilly's Last Three Years: A Company That Couldn't Keep Up With Its Own Success
How Mounjaro and Zepbound demand kept outrunning Eli Lilly's own guidance — and how the two moments that looked like trouble both turned into launching pads for the next raise.
2026-09-28Reverse DCFWhat LLY's Stock Price Is Really Betting On
Reverse-engineering the growth rate Eli Lilly's current share price already assumes — and why the answer swings wildly depending on which year's cash flow you use as a baseline.
2026-09-28Company SnapshotAbbVie (ABBV): What This Company Actually Does
A plain-English read of AbbVie's business model, built directly from its SEC filings — no hype, just where the money comes from.
2026-09-27The StoryAbbVie's Last Three Years: 'Raising Guidance' While the Number Keeps Falling
How a CEO transition and a buying spree turned AbbVie's own guidance language into a puzzle worth decoding every quarter.
2026-09-27Reverse DCFWhat ABBV's Stock Price Is Really Betting On
Reverse-engineering the growth rate AbbVie's current share price already assumes — and checking it against five years of shrinking free cash flow.
2026-09-27Company SnapshotPfizer (PFE): What This Company Actually Does
A plain-English read of Pfizer's business — patented drugs and vaccines sold through a handful of wholesalers, paid for mostly by governments and insurers, not patients — built directly from its SEC filings.
2026-09-19The StoryPfizer's Story: A Guidance Cut, a Comeback, Then Two Shocks at Once
Pfizer slashed its own 2023 guidance in half and lost credibility, clawed it back with a conservative 2024 target it beat by a wide margin, then got hit by a failed obesity drug and a tariff shock in the same spring.
2026-09-19Reverse DCFWhat PFE's Stock Price Is Really Betting On
Reverse-engineering the free-cash-flow growth rate Pfizer's share price already assumes — and finding that the honest answer is Pfizer's own 5-year history is too distorted by COVID to judge it against.
2026-09-19The StoryCVS Health's Rupture and Rebuild
In three quarters, CVS went from confidently reaffirming guidance to withdrawing it entirely and replacing its CEO — while its own filings quietly rewrote the language around exactly what went wrong.
2026-09-12Reverse DCFWhat CVS's Stock Price Is Really Betting On
Reverse-engineering the free-cash-flow growth rate CVS Health's share price already assumes — and comparing it with a company whose FCF has actually been shrinking for five years.
2026-09-12The StoryJohnson & Johnson's Last Three Years: Shed, Spend, and Recover
JNJ spun off its consumer business, then used the newfound freedom to spend $18 billion on acquisitions that deliberately sacrificed short-term profit — a bet that's now paying off in new-drug growth, right as the company prepares to shed another division.
2026-09-12Company SnapshotCVS Health (CVS): What This Company Actually Does
A plain-English read of CVS Health's business model — collecting insurance premiums, then selling the same customers their prescriptions through its own pharmacies — built directly from its SEC filings.
2026-09-12Reverse DCFWhat MRK's Stock Price Is Really Betting On
Reverse-engineering the free-cash-flow growth rate Merck's share price already assumes — and finding a moderately aggressive ask that has to hold up right through Keytruda's 2028 patent cliff.
2026-09-12Company SnapshotJohnson & Johnson (JNJ): What This Company Actually Does
A plain-English read of Johnson & Johnson's business model — prescription drugs and hospital medical devices, sold through wholesalers and paid for by insurance — built directly from its SEC filings.
2026-09-12Company SnapshotThe Cigna Group (CI): What This Company Actually Does
A plain-English read of Cigna's business — selling health insurance and running Express Scripts, one of the country's largest prescription-drug middlemen — built directly from its SEC filings.
2026-09-12The StoryCigna's Story: A Crisis, a Rebate-Free Pivot, and a 17-Year CEO Handoff
Cigna went from bragging about back-to-back guidance raises to admitting it fell 'short of our expectations' within a single year — then redesigned its core PBM business model and handed the CEO job to a 30-year insider.
2026-09-12Company SnapshotMerck (MRK): What This Company Actually Does
A plain-English read of Merck's business — the cancer immunotherapy Keytruda that alone drives nearly half of company revenue, plus vaccines and animal health — built directly from its SEC filings.
2026-09-12Reverse DCFWhat JNJ's Stock Price Is Really Betting On
Reverse-engineering the free-cash-flow growth rate Johnson & Johnson's share price already assumes — and comparing it with a company whose FCF hasn't meaningfully grown in five years.
2026-09-12The StoryMerck's Story: How an '$11 Billion by 2030' Promise Quietly Disappeared
For nearly three years, Merck insisted nothing had changed about Gardasil's $11 billion 2030 target. Then a Chinese distributor's inventory glut forced a formal withdrawal — in a single earnings call.
2026-09-12Reverse DCFWhat CI's Stock Price Is Really Betting On
Reverse-engineering the free-cash-flow growth rate Cigna's share price already assumes — and finding one of the most pessimistic-looking market expectations this site has turned up.
2026-09-12The StoryUnitedHealth's Last Three Years: From 'Balanced Growth' to a Guidance Collapse — and Back
How a confidently growing insurer blew through its own 2025 guidance twice, replaced its CEO, and has spent the months since trying to rebuild trust on a much lower bar.
2026-09-06Reverse DCFWhat UNH's Stock Price Is Really Betting On
Reverse-engineering the growth rate UnitedHealth's share price already assumes — and comparing it with the company's actual growth record, both before and after its 2025 crisis.
2026-09-06Company SnapshotUnitedHealth Group (UNH): What This Company Actually Does
A plain-English read of UnitedHealth's business model — insurance premiums plus the clinics and pharmacies its own members use — built directly from its SEC filings.
2026-09-06